Myocardial infarctions and acute coronary syndrome affect nearly 1 million Americans every year. These events result in damage to the heart tissue and lead to hospitalization with high levels of morbidity and mortality. Cardiac troponin is a biomarker that is elevated in plasma following these events but it lacks the sensitivity to detect early stage disease. New research has identified a more sensitive biomarker, cardiac myosin binding protein-C, that increases in blood concentration rapidly after a cardiac event and therefore may serve as a better clinical marker of cardiac damage.